Literature DB >> 8252509

Combination treatment in M1 prostate cancer.

P Ferrari1, G Castagnetti, G Ferrari, C A Pollastri, F Tavoni, A Dotti.   

Abstract

The treatment of advanced prostate cancer is based on hormone manipulation to eliminate the trophic effect of testosterone on sensitive androgen tissue of the tumor. In this study, we evaluated the efficacy of the partial androgen blockage versus the complete androgen blockage. One hundred, twenty-two patients were entered in this study and randomly were treated with buserelin alone or with buserelin and flutamide. The group that received buserelin was given cyproterone acetate (200 mg/day) during first 3 weeks of treatment to avoid "flare-up". During the follow-up (range 0-244 +/- 1 weeks), we evaluated 59 patients (61.4%) that had positive response and 37 patients (38.6%) that showed progressive disease: There were no statistically significant differences between the two treatment groups, not even in the evaluation of median time to response and of median time to treatment failure. In conclusion, the results emphasize that total androgenic blockage is as effective as a luteinizing hormone-releasing hormone analog used alone.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8252509     DOI: 10.1002/1097-0142(19931215)72:12+<3880::aid-cncr2820721724>3.0.co;2-4

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  Flare Associated with LHRH-Agonist Therapy.

Authors:  I M Thompson
Journal:  Rev Urol       Date:  2001

2.  Degarelix monotherapy compared with luteinizing hormone-releasing hormone (LHRH) agonists plus anti-androgen flare protection in advanced prostate cancer: an analysis of two randomized controlled trials.

Authors:  Peter Iversen; Jan-Erik Damber; Anders Malmberg; Bo-Eric Persson; Laurence Klotz
Journal:  Ther Adv Urol       Date:  2015-12-16

3.  Controversies in the management of advanced prostate cancer.

Authors:  C J Tyrrell
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

4.  Patterns of Bicalutamide Use in Prostate Cancer Treatment: A U.S. Real-World Analysis Using the SEER-Medicare Database.

Authors:  Jennifer L Beebe-Dimmer; Julie J Ruterbusch; Lauren C Bylsma; Christina Gillezeau; Jon Fryzek; Neil M Schultz; Scott C Flanders; Arie Barlev; Elisabeth Heath; Ruben G W Quek
Journal:  Adv Ther       Date:  2018-06-26       Impact factor: 3.845

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.